QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Presents Clinical Data from Ongoing Bria-IMT Trial at SABCS

Biotechnology company BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT) recently presented data from its ongoing trial during the San Antonio Breast Cancer Symposium (“SABCS”), one of the largest breast cancer conferences in the world. An article discussing the company reads, “The December 6 conference poster session presentation showed safety and efficacy results of BriaCell’s phase I/IIa targeted immunotherapy trial in patients with advanced breast cancer, as well as the early safety data of the combination study of Bria-IMT™ with KEYTRUDA®. KEYTRUDA® targets protein PD-1, which can block immune system cells from fighting off tumor cells. KEYTRUDA® attempts to “release the brakes” set in place by PD-1 and let the immune system do its work. BriaCell believes that the combination of Bria-IMT™ with KEYTRUDA® will be much more effective in killing the tumor cells compared with using either of the drugs alone.”

To view the full article, visit http://ibn.fm/u46Pc

About BriaCell

BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com.

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php